<DOC>
	<DOCNO>NCT01713946</DOCNO>
	<brief_summary>This study evaluate efficacy safety two trough-ranges everolimus give adjunctive therapy patient tuberous sclerosis complex ( TSC ) refractory partial-onset seizure . The study consist 4 phase patient [ Baseline phase : From Screening Week -8 ( V1 ) randomization visit Week 0 ( V2 ) ] , Core phase , randomization Week 0 ( V2 ) Week 18 ( V11 ) ] , Extension phase Week 18 ( V11 ) 48 week last patient complete core phase , Post Extension Phase [ end Extension phase August 31 , 2017 ] .</brief_summary>
	<brief_title>A Placebo-controlled Study Efficacy &amp; Safety 2 Trough-ranges Everolimus Adjunctive Therapy Patients With Tuberous Sclerosis Complex ( TSC ) &amp; Refractory Partial-onset Seizures</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Male female age 2 65 year ( except Europe minimum age 1 ) . 2 . Clinically definite diagnosis TSC per modify Gomez criterion 3 . Diagnosis partialonset epilepsy accord classification International League Against Epilepsy ( 1989 ) revise 2009 . 4 . Uncontrolled partialonset seizure ; must meet following : 1 . At least 16 report quantifiable partialonset seizure Baseline period continuous 21day seizurefree period Visit 1 ( Screening Visit ) Visit 2 ( Randomization visit ) , per data capture daily seizure diary . 2 . Prior history failure control partialonset seizures despite treat two sequential regimen single combine antiepileptic drug . 3 . Prior concurrent use vagal nerve stimulator ( VNS ) allow . If patient use VNS , device stimulator parameter must remain constant throughout study . 4 . Prior epilepsy surgery allow perform least 12 month study entry . 5 . Must receive one , two , three AEDs stable dose least 4 week start 8week prospective Baseline phase , remain regimen throughout Baseline phase , intend continue regimen throughout 18week double blind Core phase ( rescue medication permit ) . 6 . If female child bear potential , documentation negative pregnancy test time inform consent must use highly effective contraception study 8 week stop treatment 7 . Sexually active male must use condom intercourse take study drug , 8 week stop study treatment 8 . Hepatic , renal blood laboratory value within follow range screening : 1 . AST ALT level &lt; 2.5 x ULN 2. serum bilirubin &lt; 1.5 × ULN ( limit apply patient elevate indirect bilirubin , Gilbert 's Syndrome ) , 3. serum creatinine &lt; 1.5 x ULN 4. hemoglobin ≥ 9 g/dL 5. platelet ≥ 80,000/mm3 6. absolute neutrophil count ≥ 1,000/mm3 9 . Written informed consent . Subjects legal guardian must ability comprehend informed consent form willing provide inform consent . 10 . Patient caregiver must able reliably record seizures keep daily diary recall adverse event . 1 . Patients seizures secondary metabolic , toxic , infectious psychogenic disorder drug abuse current seizure relate acute medical illness . 2 . Presence nonmotor partial seizure ( NOT APPLICABLE per Amendment 2 ) 3 . Patients TSC SEGA need immediate surgical intervention . 4 . Patients 2 year age untreated infantile spasm . 5 . Within 52 week prior study entry , episode status epilepticus define protocol . 6 . Patients history seizure cluster ( individual seizure accurately count accord judgment investigator ) occur within 26 week prior study entry . 7 . Patients require rescue medication baseline phase 6 day 8 . Patients nonTSC related progressive encephalopathy . 9 . Patients weigh less 12 kg . 10 . Patients coexist malignancy within 3 year prior randomization , except adequately treat carcinoma cervix basal squamous cell carcinoma skin . 11 . Patients severe and/or uncontrolled medical condition randomization : 1 . Symptomatic congestive heart failure New York Heart Association Class III IV , history leave ventricular ejection fraction ( LVEF ) &lt; 50 % , QTc interval &gt; 460ms , congenital QT syndrome , unstable angina pectoris , myocardial infarction within 6 month study entry , serious uncontrolled cardiac arrhythmia clinically significant cardiac disease . 2 . Significant symptomatic deterioration lung function 3 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption everolimus ( e.g. , ulcerative disease , malabsorption syndrome small bowel resection ) . 4. liver disease cirrhosis , decompensated liver disease , chronic hepatitis 5 . Uncontrolled diabetes define fast serum glucose &gt; 1.5 × ULN . 6 . Active skin , mucosa , ocular GI disorder Grade &gt; 1 . 7 . Active ( acute chronic ) uncontrolled severe infection . 8 . A known history HIV seropositivity active viral infection . 12 . Patients active , bleeding diathesis . 13 . Patient uncontrolled hyperlipidemia : fasting serum cholesterol &gt; 300 mg/dL OR &gt; 7.75 mmol/L AND fast triglyceride &gt; 2.5 x ULN . 14 . Patients major surgery significant traumatic injury within 4 week study entry . 15 . Patients prior history organ transplant . 16 . Patients receive 3 antiepileptic drug time baseline phase randomization change dose AEDs 4 week screen baseline period . 17 . Patients treated felbamate , unless treatment continuous ≥ 1 year . 18 . Patients currently receive anticancer therapy receive anticancer therapy within 4 week study entry ( include chemotherapy , radiation therapy , antibody base therapy , etc. ) . 19 . Prior treatment investigational drug within precede 4 week prior study entry . 20 . Patients receive chronic , systemic treatment corticosteroid another immunosuppressive agent study entry . Topical inhale corticosteroid allow . 21 . Patients receive prior treatment systemic mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) within 24 month study entry . Patients receive prior treatment topical mTOR inhibitor ( sirolimus , temsirolimus , everolimus ) within 4 week study entry . 22 . Patients know hypersensitivity everolimus rapamycinanalogues ( sirolimus , temsirolimus ) excipients . 23 . Patients history noncompliance medical regimen consider potentially unreliable able complete entire study 24 . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive hCG laboratory test . 25 . Patients Score 4 5 Suicidal Ideation item within 2 year Screening , `` yes '' Suicidal Behavior item ColumbiaSuicide Severity Rating Scale Screening Baseline , upon follow healthcare professional find severely depressed suicidal . 26 . Maintenance diet consist &lt; 40 g carbohydrate per day within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>TSC seizure ,</keyword>
	<keyword>TSC epilepsy ,</keyword>
	<keyword>mTOR inhibitor ,</keyword>
	<keyword>RAD001 ,</keyword>
	<keyword>Everolimus</keyword>
</DOC>